Table 3.
Measurement | Before anti-IL-5 | After anti-IL-5 | ||||||
---|---|---|---|---|---|---|---|---|
0 h (pre-challenge) | 48 h post-challenge | 0 h (pre-challenge) | 48 h post-challenge | |||||
rs | P | rs | P | rs | P | rs | P | |
KIM-127 (intermediate- and high-activity β2) | 0.74 | 0.05 | 0.32 | 0.50 | −0.31 | 0.50 | −0.18 | 0.71 |
β2 | 0.62 | 0.09 | 0.05 | 0.91 | −0.27 | 0.45 | 0.02 | 0.96 |
αM | −0.20 | 0.58 | 0.38 | 0.31 | 0.24 | 0.51 | 0.15 | 0.68 |
αL | 0.41 | 0.25 | 0.35 | 0.36 | 0.22 | 0.58 | −0.02 | 0.96 |
N29 (intermediate- and high-activity β1 | 0.30 | 0.41 | 0.33 | 0.39 | 0.28 | 0.43 | 0.12 | 0.76 |
β1 | 0.25 | 0.49 | −0.03 | 0.95 | 0.28 | 0.42 | −0.12 | 0.75 |